BioVentrix Advances Its Revivent-TC Ventricular Enhancement Technology For Heart Failure

BioVentrix Inc. has its sights set on US market approval for its hybrid transthoracic-endovascular Revivent-TC system, a unique device that enables a minimally invasive approach to treating patients who develop ischemic heart failure following a heart attack.

Heart failure (HF), the leading cause of hospitalization in Americans over age 65, is both progressive and progressing. Driven by the aging population and an increase in ischemic heart disease, hypertension, and diabetes, the number of Americans with HF is projected to climb 46% from five million in 2012 to eight million in 2030, according to the American Heart Association. What’s more, the direct and indirect costs of treatment are forecast to more than double from $31 billion to $70 billion in the same time period. Despite advances in pharmacological and device therapy over the years, the prognosis for patients with this disease has not been impacted significantly, and HF continues to loom as a new epidemic in cardiovascular medicine. Privately held, San Ramon, CA-based BioVentrix Inc. hopes to change this trajectory of patient outcomes with a unique, minimally invasive approach to treating patients who develop ischemic HF following a heart attack. It’s the Revivent-TC Ventricular Enhancement System, which employs titanium anchors to reshape the scarred and enlarged left ventricle of the heart and enhance myocardial pumping efficiency, and it is showing promise for those who have suffered a heart attack but are too sick to tolerate invasive heart surgery.

BioVentrix’s goal is to offer a treatment option for patients prior to them needing a ventricular assist device (VAD) that can get them out of the hospital faster than with...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Europe

Swiss Medtechs Advised To Work On US Tariff Mitigation Strategies

 
• By 

The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.

Inclusive By Design: UK Invites Sponsors To Submit Trial Diversity Plans

 
• By 

The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.

Plans For Specific EU Orphan And Pediatric Device Expert Panel Need To Go Further

 

Moves are at last underway for a more specific focus on orphan and pediatric devices. They are a start; but experts are calling for more to support this sector.

MORE Details On MHRA’s Online Platform For Post Market Surveillance

 
• By 

Post-market surveillance regulations for medtech system users in Great Britain coming into force on 16 June will make new data requirements under new compliance deadlines.

More from Geography

Guardant Health Launches Germline Hereditary Cancer Test

 

Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.

Data Finds Capillary Blood Is A Reliable Alternative To Venous Blood For Routine Testing

 

A study from Babson Diagnostics published in the peer-reviewed Journal of Applied Laboratory Medicine showed that capillary blood sample volume issues can overcome historical challenges, such as poor quality, through a technique called assay miniaturization.

Inclusive By Design: UK Invites Sponsors To Submit Trial Diversity Plans

 
• By 

The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.